Novartis: FDA breakthrough therapy for lung cancer treatment

(CercleFinance.com) - Novartis received breakthrough therapy designation from the US Food and Drug Administration for an investigational treatment for lung cancer, the Swiss drugmaker said on Friday.


The FDA granted breakthrough therapy designation to capmatinib (INC280) as a first-line treatment for patients with metastatic MET exon14 skipping-mutated non-small cell lung cancer.

There are currently no targeted therapies approved to treat MET exon14 skipping-mutated non-small cell lung cancer, a particularly aggressive form of the disease.

The FDA's breakthrough therapy label is meant to accelerate the development of drugs targeting life-threatening conditions.

Copyright (c) 2019 CercleFinance.com. All rights reserved.